Expect Trikafta to Be a Game Changer for Cystic Fibrosis

February 2020

Trikafta (try-KAF-tuh, elexacaftor/tezacaftor/ivacaftor) will be a game changer for treating cystic fibrosis (CF).

It targets a gene mutation found in nearly 90% of CF patients.

Prior CF transmembrane conductance regulator (CFTR) modulators...Kalydeco, Orkambi, and Symdeko...target genetic mutations found in fewer than 50% of patients.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Diuretics Know Rules of Thumb to Manage Loop Diuretics
Med Administration Evaluate Whether to Redose Meds After Vomiting
Acne Don't Jump to Aklief or Amzeeq for Acne
Hepatitis C Anticipate More Screening and Treatment for Hep C
Parkinson's Disease Advise Saving Nourianz as a Last Resort for Parkinson's
Nutrition Answer Questions About Plant-Based, Non-Dairy Milks
Med Safety Recommend Eye Exams for Patients on Elmiron
Cystic Fibrosis Expect Trikafta to Be a Game Changer for Cystic Fibrosis
Practice Educate Patients on Ways to Improve the Taste of Meds
Contraceptives Dispel Concerns About Continuous Contraception
Cardiology Be Alert for Colchicine Uses Other Than Gout
Practice Watch for Confusing Med Expiration Dates

Expect Trikafta to Be a Game Changer for Cystic Fibrosis

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents